Global Transcriptomics Market 2016-2020
Transcriptomics involves the collection and analysis of transcriptomes of different types of cells or tissues present in an organism. The transcriptome characterizes the set of all RNA molecules, which is a part of the genetic code. The difference in genetic expression symbolizes the wide-ranging biochemical and physical differences present among various cells and tissues that may cause genetic disorders.
Technavio’s analysts forecast the global transcriptomics market to grow at a CAGR of 14.10% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global transcriptomics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of the transcriptomics consumables, and transcriptomics instruments.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Transcriptomics Market 2016-2020
Technavio recognizes the following companies as the key players in the global transcriptomics market: Agilent Technologies, Illumina, Roche Diagnostics, Thermo Fisher Scientific, Beckman Coulter, Becton, Dickinson and Company, Biological Industries, bioMérieux, Bio-Rad Laboratories, Cepheid, Clontech Laboratories, Cytognomix, Edico Genome, Eppendorf, Fluidigm, GE Healthcare, Harvard Bioscience, Kapa Biosystems, Leica Biosystems, Maxim Biotech, Molecular Devices, Oxford Gene Technology, PerkinElmer, Promega, Qiagen, RainDance Technologies, Siemens Healthcare, and Sigma-Aldrich.
Commenting on the report, an analyst from Technavio’s team said: “Growing popularity of single cell transcriptomics will be a key trend for market growth. Conventionally, transcriptomics for gene expression measurements were used for bulk sampling that included many cells. However, advances in technology, coupled with the need for specific analysis and results, have driven the need for single cell transcriptomics, which has been extensively used for analyzing rare cell populations such as circulating tumor cells, cancer stem cells in solid tumors, and embryonic stem cells in mammalian blastocysts. Technological advances in single cell transcriptomics have enabled users to carry out live cell imaging and lineage tracing.”
According to the report, one of the key drivers for market growth will be rise in strategic initiatives among vendors. Globally, there has been an increase in strategic initiatives among vendors in the transcriptomics market, which has significantly impacted demand in different regions. Strategic initiatives are primarily to leverage on each other’s USP and that could be a strong customer base, technology, strong financial capability, or R&D capabilities to increase market share and strongly establish presence in the transcriptomics market. For instance, in February 2014, Thermo Fisher (based in the US) acquired Life Technologies for $13.6 billion, which includes business divisions such as sera and media, chromatography instruments, purification consumables, and DNA sequencing. The combination of these two companies will provide access to advance technologies for genomics and proteomics, to accelerate life sciences research. Apart from helping the concerned vendors to expand their respective product portfolios, strategic initiatives have helped global vendors to venture into untapped markets, especially in developing countries, to launch products by leveraging on a local player’s market presence.
Further, the report states that commercialization of transcriptomics products is a challenging process. Some of its products come under the medical devices category as they are used by physicians for diagnostic purposes. The FDA categorizes medical devices, including the ones used for conducting genetic tests (including transcriptomics solutions), into three separate classes, ranging from class I (for relatively low risk products), to class III, (tests are subject to the greatest level of scrutiny). Therefore, they cannot be marketed without successfully completing clinical trials, which is a time consuming, expensive, and uncertain process. The regulations for approval on diagnostics devices vary across countries, which is a major challenge faced by MNCs.
Agilent Technologies, Illumina, Roche Diagnostics, Thermo Fisher Scientific, Beckman Coulter, Becton, Dickinson and Company, Biological Industries, bioMérieux, Bio-Rad Laboratories, Cepheid, Clontech Laboratories, Cytognomix, Edico Genome, Eppendorf, Fluidigm, GE Healthcare, Harvard Bioscience, Kapa Biosystems, Leica Biosystems, Maxim Biotech, Molecular Devices, Oxford Gene Technology, PerkinElmer, Promega, Qiagen, RainDance Technologies, Siemens Healthcare, and Sigma-Aldrich.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook